Navigation Links
Curoverse Announces Arvados Open Source Platform for Managing and Processing Genomic and Other Big Data Now Available on Microsoft Azure
Date:2/10/2016

Curoverse announced today that the open-source, multi-platform Arvados system is now available on Microsoft Azure. On Azure, Arvados provides capabilities for managing and processing genomic and health data at petabyte scale.

“We saw clear demand for Microsoft Azure from major institutions collecting and analyzing genomic data,” said Adam Berrey chief executive officer at Curoverse. “Microsoft Azure offers powerful capabilities and broad institutional support for research and pharmaceutical organizations, so we are excited to collaborate with Microsoft to deliver Arvados on Azure.”

The Arvados platform is being adopted by major genomic sequencing centers in the US, Europe, and Asia to meet the big data management and processing issues created by next generation sequencing as well as the analysis of related data such as RNA, microbiome, and imaging. Curoverse is working with Microsoft to help customers take advantage of Azure capabilities such as scalable compute, rapid deployment of new clusters, control over data locality, and high-speed connectivity to research institutions. The company is also collaborating with Microsoft to develop new genomic pipeline benchmarking tools that will be available on Azure.

“We are committed to empowering scientists and health professionals to solve the world’s biggest challenges by offering choice and flexibility of technology,” said David Heckerman, Distinguished Scientist at Microsoft Corp. “As a service layer on top of Azure, Arvados accelerates scientific discovery and clinical diagnostics using genomic and health data. The Arvados platform builds on Azure with advanced capabilities for managing large collections of files and reliably running reproducible computational workflows.”

Unlike software-as-a-service solutions for managing and processing genomic data, Arvados can be installed in an organization’s existing Microsoft cloud infrastructure or on-premises computing infrastructure. As a result, organizations using Arvados do not need to transfer their data or code outside of systems they control. In addition to control and security, this gives customers access to the most competitive cloud pricing and complete transparency. Curoverse provides a subscription service for maintaining, supporting, and operating Arvados clusters in the cloud and on-premises.

The source code for Arvados can be downloaded now from the Arvados project (https://arvados.org) or on Github (https://github.com/curoverse/arvados), and users can try the solution using a trial cluster operated by Curoverse on Azure (http://lp.curoverse.com/free-arvados-trial/).

ABOUT CUROVERSE, INC.
Curoverse is an investor-backed software company and the largest contributor to the free and open source Arvados big data platform. Curoverse provides a subscription service to ensure the success of organizations using Arvados in the cloud and on-premises. The company is based in Massachusetts and more information is available at http://curoverse.com.

Read the full story at http://www.prweb.com/releases/2016/02/prweb13203541.htm.


'/>"/>
Source: PRWeb
Copyright©2016 Vocus, Inc.
All rights reserved


Related biology technology :

1. Curoverse Announces New Infrastructure Software for Precision Medicine, Genomics and Bioinformatics
2. Curoverse Raises $1.5 Million to Build Open Source Platform for Genomic and Biomedical Big Data
3. Global Stem Cells Group Announces Agreement with Singapore Stem Cell Training Network
4. BIOREM announces nomination to the TSX Venture 50 finalists
5. Novan Announces Robert A. Ingram as Chairman
6. Novogen Announces Changes to the Board with New Chairman and Deputy Chairman Appointed
7. Sangamo BioSciences Announces Presentation At The Leerink Partners 5th Annual Global Healthcare Conference
8. Shimadzu Scientific Instruments Announces Product Showcases, Live Demos, Posters and Presentations at Pittcon 2016
9. Sinovac Announces Receipt of Competing Non-Binding "Going Private" Proposal
10. ProMIS Neurosciences Announces Identification of a Second Novel Therapeutic Target for Alzheimer’s Disease
11. Symphony Technology Group Announces Sale of AlphaImpactRx to IMS Health
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/8/2019)... NEW YORK (PRWEB) , ... September 04, 2019 ... ... New York Academy of Sciences announced today the three Winners and ... Supporting outstanding postdoctoral scientists from academic research institutions across New York, New Jersey, ...
(Date:8/29/2019)... ... August 28, 2019 , ... DuPont Nutrition & ... to attendees at the International Baking Industry Expo, September 8 to 11, in ... production efficiency to cost and waste reduction and from maintaining freshness throughout shelf ...
(Date:8/23/2019)... ... 2019 , ... The EnozoPro® converts ordinary tap water into a sanitizing spray ... hard surfaces including E. Coli, Salmonella, MRSA, Listeria and Legionella. It works as a ... the product page at rovingblue.com , ”At Enozo, our mission is to develop solutions ...
(Date:8/8/2019)... ... August 08, 2019 , ... Inference Solutions , ... organizations, today announced that the company’s Studio Intelligent Virtual Agent (IVA) platform earned ... Inference will officially accept the award at Frost & Sullivan’s annual Excellence in ...
Breaking Biology Technology:
(Date:8/19/2019)... ... August 19, 2019 , ... Since the ... of ultra-thin two dimensional slices which are placed on microscope slides, stained and ... tissues and complicated features such as vasculature and thus researchers in the last ...
(Date:8/14/2019)... ... August 14, 2019 , ... Carterra® ... they have opened a Customer Experience Center (CEC) and office in Munich, Germany. ... office. , The Munich CEC will be a place for researchers throughout Europe ...
(Date:8/14/2019)... Calif. (PRWEB) , ... August 13, 2019 , ... Dr. Julie Reck of Veterinary ... to her patients. Her first stem cell patient, her own geriatric Australian Shepherd, ... According to Dr. Reck, Simon wanted to play but his body was weak, and he ...
Breaking Biology News(10 mins):